Q32 Bio (QTTB) director gets 9,810 options at $12.64, benefits to OrbiMed

Rhea-AI Filing Summary

Q32 Bio Inc. director and ten percent owner Diyong Xu received a grant of stock options covering 9,810 shares of common stock at an exercise price of $12.64 per share. These options expire on June 11, 2036.

The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, subject to Xu’s continued service. Under an agreement with OrbiMed entities, any securities or economic benefits from these options must be transferred to OrbiMed-related funds.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Xu Diyong

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,810	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 9,810 shares (Direct, null)

Footnotes (1)

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.

Key Figures

Option grant size: 9,810 shares Exercise price: $12.64 per share Expiration date: June 11, 2036 +2 more

5 metrics

Option grant size 9,810 shares Stock Option (Right to Buy) granted to Diyong Xu

Exercise price $12.64 per share Conversion or exercise price for the stock options

Expiration date June 11, 2036 Option term end date for the grant

Underlying shares 9,810 shares Common stock underlying the stock option grant

Post-grant derivative holdings 9,810 option shares Total shares underlying options following the transaction

Key Terms

Stock Option (Right to Buy), vesting, exercise price, expiration date, +2 more

6 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vesting financial

"shares underlying this option shall vest and become exercisable in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 12.6400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders"

economic benefit financial

"transfer any securities issued under any such stock options or other awards, or the economic benefit thereof"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Diyong

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.64	06/12/2026		A		9,810		(1)	06/11/2036	Common Stock	9,810	$0	9,810	D(2)

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

2. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.

	/s/ Eric Bell, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Q32 Bio (QTTB) director Diyong Xu receive in this Form 4 filing?

Diyong Xu received a grant of stock options for 9,810 shares of Q32 Bio common stock. The options were granted at a $12.64 exercise price per share and represent equity-based compensation rather than a market purchase or sale of existing shares.

At what price can the new Q32 Bio (QTTB) stock options be exercised?

The stock options granted to Diyong Xu have an exercise price of $12.64 per share. This means Xu, or the designated economic beneficiary, can buy Q32 Bio common stock at $12.64 if and when the options vest and are later exercised.

When do Diyong Xu’s Q32 Bio (QTTB) stock options vest and become exercisable?

The options vest in full on the earlier of June 12, 2027 or Q32 Bio’s next annual stockholder meeting. Vesting is conditioned on Xu’s continued service through the applicable vesting date, after which the options become exercisable for common shares.

How many Q32 Bio (QTTB) option shares does Diyong Xu hold after this transaction?

After this grant, Xu is reported as holding stock options covering 9,810 underlying Q32 Bio common shares. This figure reflects the total derivative position from this award, which will only convert into stock if the options vest and are exercised.

Who ultimately receives the economic benefit from Diyong Xu’s Q32 Bio (QTTB) options?

Under an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, any securities or economic benefits from these options must be transferred to them. They will ensure the benefits are provided to OrbiMed Private Investments VII, LP as specified.

When do the newly granted Q32 Bio (QTTB) stock options expire?

The granted stock options expire on June 11, 2036 if not exercised earlier. After that expiration date, the right to purchase Q32 Bio common stock at the $12.64 exercise price under this particular option grant will lapse.